Marietta Wealth Management LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 5.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,568 shares of the biopharmaceutical company’s stock after purchasing an additional 3,164 shares during the period. Marietta Wealth Management LLC’s holdings in Pfizer were worth $2,230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently bought and sold shares of the company. Morgan Stanley grew its position in shares of Pfizer by 6.4% in the third quarter. Morgan Stanley now owns 46,069,866 shares of the biopharmaceutical company’s stock valued at $1,690,763,000 after purchasing an additional 2,777,676 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Pfizer by 0.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 39,996,916 shares of the biopharmaceutical company’s stock worth $1,467,887,000 after acquiring an additional 143,779 shares during the period. Sanders Capital LLC grew its position in Pfizer by 2.2% in the third quarter. Sanders Capital LLC now owns 28,895,978 shares of the biopharmaceutical company’s stock worth $1,183,645,000 after acquiring an additional 613,967 shares during the period. California Public Employees Retirement System grew its position in Pfizer by 3.0% in the fourth quarter. California Public Employees Retirement System now owns 19,516,941 shares of the biopharmaceutical company’s stock worth $718,419,000 after acquiring an additional 572,666 shares during the period. Finally, Jensen Investment Management Inc. grew its position in Pfizer by 7.3% in the third quarter. Jensen Investment Management Inc. now owns 11,168,803 shares of the biopharmaceutical company’s stock worth $409,895,000 after acquiring an additional 761,980 shares during the period. Institutional investors and hedge funds own 67.36% of the company’s stock.
Several research analysts recently weighed in on the company. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 price objective for the company. The Goldman Sachs Group set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, January 21st. DZ Bank restated a “buy” rating and set a $41.00 price target on shares of Pfizer in a research report on Wednesday, February 3rd. Barclays raised their price target on Pfizer from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Friday, December 4th. Finally, SVB Leerink lowered their price target on Pfizer from $44.00 to $40.00 and set a “market perform” rating for the company in a research report on Wednesday, February 3rd. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $39.38.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.04). The firm had revenue of $11.68 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 5th. Shareholders of record on Friday, January 29th will be issued a dividend of $0.39 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Thursday, January 28th. This represents a $1.56 annualized dividend and a dividend yield of 4.60%. Pfizer’s dividend payout ratio (DPR) is presently 52.88%.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Further Reading: What are convertible shares?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.